Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00046748
Status:
COMPLETED
Last Update Posted:
2017-08-02
First Post:
2002-10-02
Brief Title:
Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Ph III 28-wk Multicenter Randomized Double-blind Placebo-controlled Parallel-group Study to Assess Efficacy Safety Tolerability of SC Omalizumab in Adults and Adolescents w Severe Persist Allergic Asthma Are Inadequately Controlled Despite GINA 2002 Step 4 Tx
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effect of omalizumab compared to placebo on clinically significant asthma exacerbation rates in adolescents and adults with asthma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None